AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Aurinia Pharmaceuticals Inc.

4464 Markham Street
Suite 1203
Victoria, BC V8Z 7X8

Full Time Employees39

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard M. GlickmanFounder, Chairman, Pres & CEO943.68kN/A1958
Mr. Michael R. MartinCo-Founder & COO333.34kN/AN/A
Mr. Dennis Bourgeault CPA, C.A.CFO & Sec.306.48kN/AN/A
Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C)Exec. VP of Corp. Devel.412.19kN/AN/A
Dr. Neil Solomons M.D.Chief Medical Officer466.61kN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Corporate Governance

Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of April 1, 2019 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.